January 9, 2013

1. The Breast Health Company™ A New Paradigm for Preventing Breast Cancer January 9, 2013 NASDAQ: ATOS 1

2. Forward Looking Statement This presentation has been prepared by Atossa Genetics, Inc. (the “Company”) as of January 8, 2013. It should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company or as an inducement to make an offer or invitation with respect to those securities. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of any individual investor. It is not investment advice and prospective investors should obtain their own independent advice from qualified financial advisors having regard to their objectives, financial situation and needs. Certain statements contained herein, including, without limitation, statements containing the words “believes,” “intends” and other words of similar import, constitute “forward-looking statements” within the meaning of section 7a of the Securities Act of 1933, as amended, and section 21e of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual results to differ materially from projected results. Accordingly, investors should not place undue reliance on forward-looking statements as a prediction of actual results. The forward-looking statements may include projections and estimates, the timing and success of specific projects and our future operating results and financial condition. When we use the words "will," "believe," "intend," "expect," "may," "should," "anticipate," "could," "estimate," "plan," "predict," "project," or their negatives, or other similar expressions, the statements which include those words are usually forward-looking statements. When we describe strategy that involves risks or uncertainties, we are making forward-looking statements. The forward-looking statements in this presentation, if any, speak only as of the date of this presentation; we disclaim any obligation to update these statements. We have based these forward-looking statements on our current expectations and assumptions about future events. While our management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control. Neither the delivery of this presentation nor any further discussions by the Company or its representatives with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. This document contains confidential and proprietary information. Unauthorized possession, use or disclosure of the enclosed information is strictly prohibited and will be prosecuted under all applicable state and federal laws.

3. Mission Statement MISSION STATEMENT We are committed to building value for investors by preventing breast cancer with our patented, FDA-cleared products and our CLIA-based services NASDAQ: ATOS

4. Mission Statement GOAL FOR 2013 • National launch of the ForeCYTE Breast Health Test, The Pap Smear for Breast Cancer • $500 test for 110 Million women age 18-73 • Tactical metrics • 5,000 Independent Sales Reps calling on… • 33,000 Ob-Gyn MDs nationwide to generate… • $15,000 per MD per year in revenue • About a 1% Market Penetration NASDAQ: ATOS

5. ForeCYTE Breast Health Test • FDA-cleared non-invasive biopsy device • Made in the USA • CLIA-based • test • 17 patents

6. How does ForeCYTE work? Microscopic Results IBIS Risk Algorithm (Peer reviewed algorithm developed from a registry of 158,041 women in whom 3,257 breast cancers occurred) Personal Reproductive History Family History of Breast cancer Normal Risk <15% Intermediate Risk 15 to 20% High Risk >20%

7. ForeCYTE Value Proposition Care Path Business Model • Potential to make mammograms (39 MM/year) virtually obsolete; • Potentially eliminate the need for most of the nation's 1.2 million biopsies (at a cost of about $3500 each) and which require a needle to be jammed into the breast. • MOST IMPORTANTLY, because the Atossa test spots abnormalities years before they can turn into tumors the test opens the door to eventual prevention of breast cancer… • JUST AS THE PAP SMEAR HAS VIRTUALLY ELMINATED CERVICAL CANCER (80% reduction) IN WOMEN WHO GET REGULAR SCREENING.

8. Laboratory Service Revenue Atossa Revenue Model Laboratory Analysis with Report Generation Sampling Kit Sales to Doctors $500/patient Breast Pump and Kit Sales to Doctors

9. Reimbursement Atossa Revenue Model • Faster payments for Atossa • 1st Payer contract • 57 MM Americans covered • A stepping stone to In-network contracts over the next 2 years Laboratory Analysis with Report Generation Sampling Kit Sales to Doctors

10. Early ForeCYTE Adoption Demonstrates Significant Upside Potential34 MDs = $15,000 revenue/MD/year Cumulative Revenue x1000 Gross Profit 87%

11. National ForeCYTE Launch • Distributor network focused • Henry Schein, McKesson, PSS World Medical, Cardinal Health, VWR, Vaxserve, Mercedes Medical, Fisher, NDC members, Imco members, B&H Surgical, Marshall Medical and Cascade HealthCare Products • Collectively, over 5,000 employee or independent sales reps selling ForeCYTE products

12. Atossa Laboratory Tests

13. The Atossa Breast Health Care Path Care Path Business Model US women age 18 to 73 at risk of breast cancer Normal Risk 0 to 15% Intermediate Risk 15 to 20% High Risk >20% Newly Diagnosed Breast Cancer Breast Cancer Survivors

14. The Atossa Breast Health Care Path Care Path Business Model US women age 18 to 73 at risk of breast cancer Stratify 110 MM High Risk >20% Intermediate Risk 15 to 20% Normal Risk 0 to 15% 10 MM Assess Breast Cancer Survivors Newly Diagnosed Breast Cancer Profile Monitor 2.5 MM 0.2 MM

15. Intellectual Property Care Path Business Model • FDA Medical Device Market Authorizations • 11 510(k) cleared and 2 510-exempt • CLIA-based Laboratory Developed Tests • 4 validated tests • Patents • 179 issued and 50 pending • Trademarks • 1 registered and 7 pending

16. Management Team Care Path Business Model Experienced Management Team • CEO • Steven C Quay, MD, PhD, FCAP • CFO • Kyle Guse, Esq., CPA • CSO • Shu-Chih Chen, PhD • VP Marketing & Sales • Christopher Destro • Operations • Michael Malafronte

17. Key Financial Metrics • Revenue: $383K (9 mos. ended 9/30/12) • Gross Profit: $324K (9 mos. ended 9/30/12) • Gross profit margin: 87% (9 mos. ended 9/30/12) • Total Op Expenses: $3.7M Monthly burn rate (1H 2012) ~ $370K • Shareholder Equity: $3.4M (9/30/12) • Shares Outstanding: 12.1M common; no preferred; 7.2M warrants at $1.56 per share

18. Investment Summary Investment Considerations • Breast Health Revenue; >85% Gross Margin • Patented, FDA cleared products and services • 179 Issued Patents and 11 FDA-cleared devices • Experienced management team • Two Key 2013 milestones: • National roll out of ForeCYTE test with 5,000 sales reps • Advancing pipeline of additional products and services, including novel treatment approach NASDAQ: ATOS

19. NASDAQ: ATOS